SEHK:9926Biotechs
Assessing Akeso (SEHK:9926) Valuation After Positive Lung Cancer Data At 2026 European Lung Cancer Congress
Akeso (SEHK:9926) has come into focus after presenting new lung cancer data at the 2026 European Lung Cancer Congress. The company updated investors on cadonilimab and ivonescimab across difficult non small cell lung cancer settings.
See our latest analysis for Akeso.
Following the ELCC updates, Akeso's HK$137.8 share price sits on the back of a 25.05% 1 month share price return and 21.62% year to date share price return. The 1 year total shareholder return of 58.48% and 3 year total...